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Summary Polyethylene glycol (PEG) modification of a chimeric Fab' fragment (F9) of A5B7 (a-CEA), using
an improved coupling method, increases its specificity for subcutaneous LS174T tumours. PEGylation
increased the area under the concentration-time curve (AUCo-144) in all tissues but there were significant
differences (variance ratio test, F=27.95, P<0.001) between the proportional increases in AUCo144, with the
tumour showing the greatest increase. The increase in AUCtumour from F9 to PEG-F9 was similar to the
reported increase from Fab' to F(ab')2 while the increase in AUCbl..d by PEGylation of F9 was only 21% of
the reported increase from Fab' to whole IgG. A two sample t-test showed no significant differences between
maximal tumour/tissue ratios for PEG-F9 and F9 while the tumour/tissue ratios for PEG-F9 remained high
over a longer period, with tumour levels at least double those for F9. PEG-F9 emerges as a new generation
antibody with potential advantages for both radioimmunotherapy and tumour imaging. Since there was a
reduction in antigen binding, optimisation of PEGylation might further improve tumour specificity. The latter
resulted from complex effects on both the entry into and exit rates from tumour and normal tissues in a tissue-
specific fashion.
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Covalent modification of proteins with poly(ethylene
glycol)(PEG) has emerged as the method of choice to
overcome the major problems associated with protein
therapeutics (Francis et al., 1991; Delgado et al., 1992a).
Increased plasma half-life, increased resistance to proteolysis
and substantial reduction in antigenicity/immunogenicity
have been found in almost all recombinant and native
proteins after PEGylation. The success of this technology is
indicated by the number of PEG proteins already in clinical
trials (Francis et al., 1991).
The benefits of PEG-modification might also extend
beyond these recognised advantages, since PEG-coupled
antibodies (Kitamura et al., 1990, 1991) and PEG-coupled
liposomes (Martin et al., 1991) have recently been reported to
have tumour-localising properties. The mechanisms leading
to the improved localisation are, however, unclear. Whether
the observed tumour-localising effect simply resulted from the
longer circulation time or was related to some other
consequence of PEGylation remains to be established. PEG
changes the surface properties of the molecules and
macromolecular structures to which it is attached (Fisher et
al., 1991); short range charge-based interactions are
precluded (Fisher et al., 1991) and there is a relationship
between the extent to which this occurs and the length of the
PEG (Yoshioka, 1991). In addition, PEG alters the solubility
of molecules and this might influence the capacity of PEG
constructs to cross the extracellular matrix and other
structures, hence entry to and exit from different sites.
We have developed an improved method (Francis et al.,
1995a) for the attachment of PEG to proteins based on an
earlier method that uses activation of the polymer with tresyl
chloride (Delgado et al., 1990). The tresylated PEG
(TMPEG) has many advantages over PEGs activated by
other methods (Delgado et al., 1991; Francis et al., 1991;
Malik et al., 1992). It links PEG to proteins using mild
conditions for the coupling step, which results in a better
conservation of biological activity; the activated polymer
shows low toxicity, which allows addition of the whole
reaction mixture to biological assay systems for a rapid test
of the bioactivity of the PEG-protein conjugates (Fisher et
al., 1995; Francis et al., 1995b). The PEG is attached directly
to the molecule via a stable secondary amine linkage without
any coupling moiety (portion of the activated PEG molecule
remaining in the PEG-protein construct). The latter is
particularly undesirable since coupling moieties can react
linking further molecules, or be immunogenic/antigenic, are
sometimes toxic and potentially cleaved enzymatically. The
surface properties of the conjugate might also be affected by
a coupling moiety (by altering the charge and/or the
hydrophobicity/hydrophilicity balance). Our improved cou-
pling method thus provides a unique tool with which to study
the influence of PEGylation per se in tumour localisation.
We have PEG-modified a recombinant chimeric F(ab')
fragment (F9) with variable regions derived from A5B7 (a
murine monoclonal antibody to human carcinoembryonic
antigen) and human CHI (gamma isotype) and C kappa
constant regions using TMPEG. PEG-F9 has been used to
investigate the effects of PEG-modification on tumour
localisation using a colonic tumour xenograft, LS174T,
grown in TO nude mice.
Materials and methods
Chemicals were obtained from: MPEG (Mr 5000, Union
Carbide, USA), PEG (Mr 6000, BDH, Poole, UK), dextran
T-500 (Pharmacia, Sweden), tresyl chloride (Fluka, Switzer-
land). Phosphate-buffered saline (PBS) was from Gibco or
Sigma (Poole, UK) and '25I from Amersham (UK).
Molecular weight markers were from Sigma. A kit for
protein determination using the Coomassie brilliant blue
assay was from Pierce (Rockford, IL, USA). All other
reagents were Analar grade from BDH (Poole, UK).
Production of F9
The protocol for the production of heavy chain (VH) and
light chain (VL) cDNA of A5B7 and their subsequent cloning
into the Dl.3 Fab vector [containing the human C kappa and
human CHI (gamma isotype) constant regions] have been
recently reported (Chester et al., 1994). Briefly, VH was first
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cloned into PstI and BstEII sites in Dl.3 and the resulting
plasmid was used as the vector for insertion of VL into Sacl
and XhoI sites. The constructs were transformed into
Escherichia coli 'Sure' strain (Stratagene, La Jolla, CA,
USA). The recombinant chimeric F(ab') fragment (F9) was
isolated by affinity chromatography in a Sepharose 4B
column linked to anti-human kappa and subsequent size
exclusion chromatography in Sephacryl S-100. F9 gives
positive staining for malignant glandular structures in
human colorectal tumours consistent with staining for CEA
(Chester et al., 1994).
Iodination of F9
F9 was labelled with 125I by the chloramine T method to a sp.
act. of ca 40 MBq mg-'. Briefly, '25I was added to F9 in PBS
followed by chloramine T. After 3 min incubation on ice L-
tyrosine was added to stop incorporation to F9. The 1251-
labelled F9 was isolated from the reaction mixture by gel
filtration in Sephadex G-25 [PD-10 column from Pharmacia,
primed with 0.1% bovine serum albumin (BSA)]. This
iodination procedure has been shown to spare the integrity
of the fragment in terms of size and binding affinity to CEA
(Chester et al., 1994).
PEGylation of F9
Monomethoxypolyethylene glycol (MPEG) of 5000 Mr was
activated with tresyl chloride using a modified version
(Francis et al., 1995a) of our earlier method (Delgado et
al., 1990). MPEG is selected as the parent polymer to provide
only one active end in each molecule, thus avoiding the
formation of cross-linked products (although the polymer
attached to F9 is MPEG, the conjugates are referred to as
PEG-F9). This coupling method provides a direct linkage
between the polymer and the protein via a stable secondary
amine. The activated polymer, TMPEG, was incubated with
1251-labelled F9 (100 jug ml-') in PBS at room temperature
for 2 h using a rotary mixer. The excess TMPEG was then
inactivated by further 2 h incubation with a large excess of
glycine. The preparation was kept at 4°C before use.
Pharmacokinetic studies were performed with preparations
stored for less than 12 h. The TMPEG-treated sample was
always compared with 1251-labelled F9 subjected to the same
procedures but substituting PBS for the polymer.
Gel permeation chromatography
Reaction mixtures and sham-treated controls were chromato-
graphed on a Pharmacia fast protein liquid chromatography
(FPLC) system fitted with a Superose-12 HR 10/30 column
previously equilibrated with PBS. Since high concentrations
of TMPEG in the reaction mixtures interfere with the
resolution of the column (Malik et al., 1992), all samples
were diluted 1:50 in PBS before loading. Diluted samples
(200 jl) were eluted at a flow rate of 0.3 ml per minute with
sterile PBS; 0.25 ml fractions were collected. Protein
concentration in the fractions was established by the levels
of 1251 quantified in a gamma counter. Molecular weight
markers at concentrations of 3 mg ml-' were run similarly
and the fractions analysed for protein content using a
Coomassie Brilliant blue assay. Universal calibration of the
column (i.e. hydrodynamic radius vs elution volume) using f,-
amylase (200 kDa), alcohol dehydrogenase (yeast, 150 kDa),
BSA (66 kDa), carbonic anhydrase (29 kDa), cytochrome c
(12.4 kDa) and aprotinin (6.5 kDa) was used to estimate the
apparent hydrodynamic radius of F9 before and after
PEGylation. To convert the mol. wt. of the protein markers
to hydrodynamic radius, the relationship given by Hagel
(1988) was used.
Partition coefficient in PEG/dextran two-phase systems
The two-phase system of 5% (w/w) PEG-6000, 5% (w/w)
dextran T-500, 0.15 M sodium chloride and 0.01 M sodium
phosphate [non-charge sensitive two-phase system, (Walter et
al., 1985)] was prepared in advance from stock solutions of
20% (w/w) dextran T-500, 40% (w/w) PEG-6000, 0.5 M
sodium phosphate pH 6.8 and 0.6 M sodium chloride. After
mixing, the system was allowed to settle into the top PEG-
rich phase and the bottom dextran-rich phase at room
temperature. The top and bottom phases were stored in
separated bottles at 4°C until required. Before use the stored
phases were allowed to equilibrate to room temperature and
the biphasic system reconstituted by mixing top and bottom
phases at a 1:1 volume ratio. Aliquots (10-50 p,l) of reaction
mixtures or sham-treated control were incorporated and the
system mixed by 30-40 gentle inversions. After separation of
the phases, aliquots from top and bottom phases were
analysed for 1251 levels. The partition coefficient (K) is
calculated as the ratio between 1251 levels in top and bottom
phases.
In vivo studies
Xenografts All mice used were 2-3 months old female (TO
nude) bearing a human colon adenocarcinoma xenograft
grown in the flank for 2-3 weeks. The body weight of the
animals was 20-25 g and the average size of the tumours
was 0.625 g (mode 0.5-0.6 g). The xenograft tumour model
was developed by subcutaneous inoculation of LS174T cells
and subsequent passaging was by continuous subcutaneous
implantation from the original xenograft (Pedley et al., 1993).
The tumour is a moderately differentiated, CEA-prodticing,
adenocarcinoma with small glandular acini and which
secretes no measurable CEA into the circulation.
Biodistribution studies Sham-treated F9 and PEG-F9 were
administered intravenously (ca 8.5 ,ug) and at the indicated
time points three mice per condition were bled and killed and
the following organs removed: liver, kidney, lung, spleen,
colon, muscle and tumour. The weight of the wet organ was
recorded and the 1251 content measured in a gamma counter
(LKB, Bromma, Sweden, Wallac 1282 Compugamma).
Animals were given food and water ad libitum, the water
containing 0.1% potassium iodide in order to block thyroid
uptake. Levels of F9 and PEG-F9 are given as percent
injected radioactivity per g of blood and per cent injected
radioactivity per g of wet tissue.
Calculation of the AUCo ,44 was done by the linear trapezoid
method using the mean tissue concentrations (y) at each time
point (t). The following expression described by Yuan (1993)
was used:
AUCto-tn = 1/2(t - to))o + E 1/2(4 -ti-2)9-1+
1/2(tn-tn-l)Yn
This expression shows that the estimated AUCtO , is a
linear combination of mean concentrations at each time point
(Yuan, 1993) and therefore the variance (s.d.2) ofthe AUCto,
estimate can be calculated from the estimated standard error
(s.e.m.) of the mean tissue concentrations at each time point
using the expression described by Yuan (1993):
S.D.2(AUCto-tn) = (1/2(t1 -to)s.e.m.o)2 + E(1/2(ti-ti2)
2 ~~~~~~i2
s.e.m.i_ )2 + (1/2(tn-tn_l)s.e.m )2
Statistical analysis
The increments in AUCO 144 promoted by PEGylation were
compared using the F-test for the variance ratio. The maximal
tumour to tissue ratios for F9 and PEG-F9 in each organ were
compared using a two (unpaired) sample t-test.
Binding studies
Flat-bottomed microtitre plates receiving CEA in PBS (0.2 ,gper well) were incubated for 1 h at room temperature. Wells
were then washed with PBS and quenched with 3% BSA in
PBS (150 pl per well) for ca 2 h at room temperature. Wells
were washed twice with PBS before receiving the sample
containing F9 or PEG-F9. Incubation was carried out
overnight at room temperature and after washing three
times with PBS containing 0.05% Tween 20 and four times
with distilled water, the 1251 content in each well was
measured in a gamma counter. Neither F9 nor PEG-F9
showed any binding to PBS-coated wells.
Results
Incubation of F9 with TMPEG resulted in the formation of
species with larger molecular sizes as shown by the
appearance of faster eluting peaks in gel permeation
chromatography (Figure 1). The proportion of larger
molecular size species increased with the concentration of
TMPEG in the reaction mixture, while the proportion of
material eluting at the location of the unmodified F9
decreased (Figure 1). To confirm that the increase in
molecular size was due to the formation of PEG-F9
conjugates, the reaction mixtures and sham-treated control
(see methods) were analysed in a PEG/dextran two-phase
system. The principle exploited here is that PEG-proteins
have a higher affinity for the PEG-rich top phase than their
unmodified counterparts (Delgado et al., 1990, 1991). The
partition coefficient (ratio between protein concentrations in
top and bottom phases) of F9 in a 5% PEG-6000, 5%
dextran T500, charge insensitive two-phase system was
1.14+0.08 (mean+s.e.m, n= 5). After incubation with
TMPEG the partition coefficient increased to 4.01+0.42
(n=3) for a reaction mixture containing TMPEG at a molar
excess of 75:1 (TMPEG: free amino groups) and 6.42+ 1.23
(n= 3) when the molar excess ofTMPEG was raised to 300:1.
The increase in both molecular size and partition coefficient
confirms the formation ofPEG-F9 conjugates. The broadness
of the FPLC profiles suggests that under all reaction
conditions a mixture of PEGi-F9 conjugates of a range of
degrees of substitution (i) was produced. The increase in
partition coefficient with the molar excess of TMPEG is
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consistent with an increase in the proportion of conjugates of
higher degrees of substitution.
To test the influence of PEG modification on the tumour
localisation of the antibody fragment, PEG-F9 conjugates
were produced by incubation of F9 and TMPEG at a molar
excess of TMPEG to NH2 of 300:1 (Figure Id). These
reaction conditions were selected to minimise the contamina-
tion of the sample with unmodified F9 and to increase the
proportion of species with molecular sizes exceeding the renal
threshold.
The binding of PEG-F9 to the antigen was studied in
comparison with that of F9 in order to establish how
important this is for tumour localisation. Both untreated and
control F9 (i.e. F9 exposed to 2 h incubation in PBS at room
temperature) showed similar binding to the antigen which
was greater than antigen binding for PEG-F9 (Figure 2). In
this case, the reduced binding probably implies the presence
of one or more lysines in, or near, the antigen-binding site.
Reduction in receptor-binding affinity has previously been
observed for proteins PEGylated by earlier TMPEG methods
(Delgado et al., 1992b; Smith et al., 1991). However, this
previous method gave relatively good conservation of
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Figure 2 Binding of untreated F9 (L), sham F9 (0) and PEG-
F9 (0) to CEA in microtitre plates.
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bioactivity (Knusli et al., 1992; Malik et al., 1992), now
further improved by the modified method (Francis et al.,
1995a).
Figure 3 shows the blood clearance for F9 and PEG-F9 in
TO nude mice bearing LS174T tumours. F9 was rapidly
removed from the circulation and PEG-F9 showed the typical
enhanced life in the circulation of PEG-modified proteins.
Figure 4 compares the concentrations of F9 and PEG-F9
in LS174T tumours subcutaneously implanted in the flank.
F9 and PEG-F9 profiles in the tumour tissue run almost in
parallel, albeit with higher levels for PEG-F9 than for F9 at
all time points (Figure 4, solid lines). The AU0 44 estimates
(per cent injected 1251 h g-1) were 82.87+ 15.95 for F9 and
472.17+80.53 for PEG-F9 (i.e. almost 6-fold increase in
tumour 'dose'). Levels of F9 per g of tumour equalled levels
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of F9 per g of blood by 3 h post injection and by 10 h post
injection tumour levels already exceeded blood levels (Figure
4). For PEG-F9 tumour levels only exceeded blood levels at a
later time point, between 10 and 24 h post injection (Figure
4). It should be noted that for F9, tumour/blood ratios rise
and then fall, whereas for PEG-F9 tumour/blood ratios
increase progressively from 24 to 144 h (see below).
Figure 5 shows the biodistribution of F9 and PEG-F9 to
kidney, liver, spleen, lung, colon and muscle. In all tissues the
levels of PEG-F9 were above the levels of F9 at virtually all
time points although the proportional increase varied from
tissue to tissue and also, in contrast to the tumour, with time
post injection (i.e. biodistribution profiles for F9 and PEG-F9
do not run in parallel) (Figure 5, solid lines). The time
beyond which tissue levels exceed blood levels was tissue
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Figure 3 Disappearance of F9 (0) and PEG-F9 (40) from the
blood following intravenous administration to TO nude mice
bearing LS174T tumours subcutaneously implanted in the flank.
Data shows mean+s.e.m., n=3 (error bars for some points were
obscured by the symbol). The lines fitted are spline curves.
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Figure 4 Distribution of F9 (0) and PEG-F9 (0) to LS174T
tumours subcutaneously implanted in the flank of TO nude mice
after intravenous administration. The dashed and dotted lines
show blood levels (mean values shown in Figure 2) for F9 and
PEG-F9 respectively. Data shows mean+ s.e.m., n=3 (error bars
for some points were obscured by the symbol). The lines fitted are
spline curves.
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Figure 5 Distribution of F9 (0) and PEG-F9 (0) to kidney, liver, spleen, lung, colon and muscle following intravenous administration to
TO nude mice bearing LS174T tumours subcutaneously implanted in the flank. The dashed and dotted lines show blood levels (mean values
shown in Figure 2) for F9 and PEG-F9 respectively. Data shows mean+ s.e.m., n=3 (error bars for some points are obscured by the
symbol). The lines fitted are spline curves.
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a-specific and for all tissues longer for PEG-F9 than for F9
(Figure 5) thus PEG modification altered the pharmacoki-
netics of F9 in a tissue-specific fashion (a mathematical
analysis of these changes is given in the appendix).
The practical consequences of all the changes in the
pharmacokinetics have been summarised by comparison of:
(a) the AUCo 144 for F9 and PEG-F9 in each normal tissue
and the tumour (Table I), (b) the proportional increase in
AUCO 144 for tumour and normal tissues by PEGylation
(Table I) and (c) the tumour/blood and tumour/tissue ratios
at each time point (Figure 6).
AUC" AUCPEGF AUCPEG-FIAUCF9
(mean+s.d.) (mean +s.d.) (mean ±s.d.)
Tumour 82.67± 15.95 472.17+ 80.53 5.71 ± 1.47
Liver 31.88± 5.13 136.84+34.39 4.29± 1.28
Kidney 204.79+40.19 394.16+ 105.03 1.92+0.64
Spleen 34.16± 5.79 118.09± 30.61 3.45± 1.07
Lung 33.91 ±7.36 156.12+41.59 4.60+ 1.58
Colon 18.89 ± 3.76 86.91 ± 30.33 4.60+ 1.85
Muscle 8.64±2.14 29.49+ 8.49 3.41 + 1.29
aPer cent injected radioactivity h g-Itissue
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The tumour is the tissue receiving the greatest dose of
PEG-F9 followed by kidney (Table I). Liver, spleen, lung,
colon and muscle received a much lower dose of PEG-F9, at
least a third of the tumour dose (Table I). With unmodified
F9 the kidney received the greatest dose and although
tumour received the second highest dose, it was ca five
times smaller than that received by the kidney (Table I).
Liver, spleen and lung received similar doses of F9 and colon
and muscle received lower doses (Table I). PEGylation
increased the dose delivered to all tissues (Table I) but the
variance ratio test shows that there are significant (F=27.95,
P<0.001) differences between the proportional increases in
AUCO 144 due to PEGylation, with tumour showing the
highest increment. Thus PEG modification improves the
specificity of F9 for the tumour. The increments in AUCO0,44
were unrelated to the dose ofunmodified F9 received by each
tissue (data not shown).
The tumour/tissue ratios were also analysed as a function
of time post injection (Figure 6). For F9 in all the normal
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Figure 7 Schematic representation of the two-compartmental
model. The substance is introduced in compartment 1 and
allowed to enter compartment 2 by a linear flux governed by
k2l. The exit from compartment 2 comprises return to
compartment 1 with a rate constant k12 and destruction with a
rate constant kO2. The exit rate from compartment 1, other than
only to compartment 2 (dashed arrow) is not required for the
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tissues, excluding the kidney, tumour to tissue ratios increase
sharply to reach a maximum at 24 h (lung, liver, spleen,
colon and muscle) or 72 h (blood) followed by a marked
decline (Figure 6). The tumour to kidney ratios for F9 were
below 1 at all time points and declined with time post
injection (Figure 6). For PEG-F9, the tumour to tissue ratios
show the following patterns with time post injection: (1)
increase (blood and lung); (2) increase and then decline
(kidney, liver and muscle); and (3) increase to reach a plateau
(spleen and colon). A two sample t-test showed no significant
differences between the maximum ratio observed for PEG-F9
and F9 in any of the tissues studied. For blood and lung the
tumour to tissue ratios increased over the time window of the
study and therefore it is possible that the maximum ratio for
PEG-F9 had not been achieved. In addition, the tumour to
tissue ratios for liver, spleen and colon are maintained at high
levels for a much longer period for PEG-F9 than for F9
(Figure 6). In all tissues the highest tumour to tissue ratio for
PEG-F9 is achieved at a tumour level at least twice that for
F9 at maximal ratios.
Discussion
The F(ab') fragment of A5B7, F9 has been successfully
PEGylated using TMPEG as the activated PEG. PEG-F9
shows the extended plasma half-life typical of PEGylated
proteins. The increased plasma half-life is mainly a conse-
quence of reduced renal clearance. High levels of F9 in the
kidney at early time points suggest that F9 is rapidly cleared
by the kidney, presumably by glomerular filtration, although
some ofthe protein might be subjected to tubular reabsorption
and metabolism; however, mouse urine in contrast to human
urine contains high concentrations ofprotein due to relatively
poor tubular reabsorption (Jacoby and Fox, 1984). Rapid
renal clearance of F9 is not surprising since, despite its
molecular mass of 50 kDa (theoretical hydrodynamic radius
29.25 A), its apparent hydrodynamic radius is ca 22 A, as
estimated by gel permeation chromatography on a Superose
12 column (see legend to Figure 1). It is well established that
molecules with effective molecular radius below 20 A are freely
filtered by the glomerular capillary wall (Rabkin and Dahl,
1993). Molecules with sizes in the range 20-35 A are subjected
to glomerular filtration and the extent to which its filtration is
hindered by the glomerular barrier is directly related to its size
and also depends on charge, shape and rigidity (Arendshorst
and Navar, 1988). The glomerular capillary wall almost
completely restricts the passage of molecules of molecular
radius greater then 35 A. PEG-F9 is a heterogeneous
preparation with species sp,anning a range of apparent
hydrodynamic radii from 29 A to > 40 A (as measured with
the Superose 12 column). Thus some of the PEGi-F9 species
are excluded by the glomerular barrier while others are filtered
to some extent. Since a relatively high proportion of PEG-F9
is detected in the kidney, it is presumed that the filtered species
are reabsorbed by the renal tubules (the presence of PEG
might compromise catabolism since PEG proteins are
relatively resistant to proteolysis, but this needs to be
established).
The immediate consequence of the reduced renal clearance
is increased plasma and tissue levels (i.e. increased AUC).
There were statistical differences between the proportional
increases in AUCO 144 due to PEGylation in the different
tissues. The AUCO 144 increased proportionally more for the
tumour than for the normal tissues and thus there is
increased specificity for the tumour. The different propor-
tional increases in AUCO ,. between the tissues might
provide an additional unexpected benefit by increasing the
effectivity of PEG-modified conjugates towards tumours
located in tissues which exclude the PEG protein to a
greater extent than the unmodified counterpart.
In order to establish any possible advantage of PEG-F9
over the antibody forms already in use in the clinic [whole
IgG, F(ab')2 fragments] we have compared the effect of
PEGylation on tumour localisation of F9 with that reported
for other forms of A5B7, whole IgG, F(ab')2 and Fab'
(Pedley et al., 1994). For this purpose the AUC for tumour
and blood were calculated between 3 and 144 h using the
mean concentrations for 3 h, 24 h and 144 h, which were the
only three time points used in both studies. The increase in
AUC3 144 for the tumour following PEGylation of F9 was
similar to the increase in AUC3144 from Fab' to F(ab')2. This
was achieved with an increase in AUC3-44 for blood by
PEGylation of F9, which corresponds to only 21% of the
increase in AUC3 144 from Fab' to whole IgG. Thus PEG-F9
provides a dose to the tumour similar to that provided by
conventional F(ab')2 fragments, while keeping the dose to the
blood (and hence to the bone marrow) well below that
delivered by the whole IgG. These features, together with the
generic benefits that PEGylation conveys to protein
therapeutics (Francis et al., 1991; Delgado et al., 1992a),
suggests that PEG-F9 might be superior to F(ab')2 fragments,
currently the most promising agent in clinical trials
(Bucheggar et al., 1990; Yorke et al., 1991; Pedley et al.,
1993; Lane et al., 1994), for radiommunotherapy.
PEGylation not only increased the total dose of F9
delivered to the tumour but also provided high tumour to
tissue ratios (similar or greater for PEG-F9 than for F9) and
over a longer period of time. In addition these improved
tumour to tissue ratios are achieved with tumour levels at
least twice those of F9 at maximal ratios in all tissues. Thus
PEG-F9 should prove more powerful than F9 for both drug
delivery and tumour imaging.
The binding of the fragment to the antigen was reduced
after PEGylation, thus it is encouraging to have achieved an
increase in tumour specificity, in the face ofthis loss. It should
be noted that the coupling of PEG to the antibody can be
optimised for maximum retention of antigen binding (for
example, via PEGylation in the presence of antigen to mask
the binding site). This might further improve the tumour
specificity. However, the reduced antigen binding of PEG-F9
might have been beneficial. Although, at relatively high doses,
antibody tumour uptake increases with its affinity for the
antigen (Thomas et al., 1989), it is well established that
antigen-antibody interaction can retard antibody percolation
beyond the tumour cells nearest to the capillaries, thus
constituting a 'binding site barrier', which results in a more
heterogeneous distribution (Fujimori et al., 1989).
In order to gain insight into what changes to the rates of
entry into and exit from the tissues were responsible for the
increased tumour specificity, a two-compartment model that
provides a numerical solution for these rates has been used
(see appendix). PEGylation had a variety of effects on transit
into and out of normal tissues and the tumour. Since these
complex effects may relate to more than one property of
PEG, optimisation of these encouraging early results will
need systematic dissection of the impact of factors such as
PEG chain length and degree of substitution on individual
transfer rates. To that end, investigation of more direct
measurements of tumour uptake and egress, using animal
models such as those of Tozer et al. (1994) would be
beneficial. In addition, development of improved mathema-
tical modelling tools for the study ofbiodistribution would be
useful.
Abbreviations
F9, recombinant chimeric F(ab') fragment; PEG-F9, PEGylated
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poly(ethylene glycol); CEA, carcinoembrionic antigen.
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In order to obtain insight into what changes to the pharmacokinetic
parameters led to the improved tumour specificity of F9 and why it
was tissue specific, estimates for the rates of transfer from blood to
tissues and out of the tissues (KS. and Kut, respectively) have been
obtained using a two-compartmental model that calculates a nume-
rical solution for the KS and Kut by linear regression of the data for
concentration in tissue, AUC for blood and AUC for tissue at every
time point (AH, manuscript in preparation). This approach circum-
vents some of the problems inherent in modelling multicompartment
systems in which unique solutions to parameter estimates can be an
untractable obstacle.
Briefly, for a two-compartment model with a linear flux from com-
partment 1 to compartment 2 (governed by the rate constant k21) and
a linear flux out of compartment 2 (determined by the rate constants
k12 and kO2) (Figure 7), the mass balance for a substance in com-
partment 2 is given by the differential equation:
d =k21q1- (k12 +ko2)q2 (1)
where q, and q2 are the concentrations of the substance in compar-
tments 1 and 2 respectively.
Equation (1) can be re-written as:
dq2 = k21q1 di - (k12 + ko2)q2dt (2)
If the substance is introduced at time zero into compartment 1, the
concentration of the substance in compartment 2 at the generic time
t, q2,, is obtained by integration of equation (2) between zero time
and the generic time t:
q2(t) = k2jAUC1- (k12 +k02)AUC2 (3)
AUC1 and AUC2 represent the area under the concentration-time
curve between times zero and t for compartments I and 2 respecti-
vely. Equation (3) can be regarded as a function of the type:
X = a-r +bxr
where y, xl and x2 stand for q2, AUC1 and AUC2, respectively. Best-
fit values for a and b (which give k21 and (k12+ko2) reCtively) can
therefore be obtained by linear regression, minimising the residual
sum of squares. Although in strict terms AUC, and AUC2 are not
independent vanables (both are functions of time), the estimates
obtained for the constants in all tissues and the tumour (see below)
allowed the generation of concentration versus time curves that clo-
sely matched the experimental values (AH, manuscript in prepara-
tion).
If compartment 1 represents the blood and compartment 2 repre-
sents the tissue then k21 and (kl2+kkOJ are esimtes for Kn and K-Out
respectively calculated by linear regression of the data for concentra-
tion in the tissue, AUCb, and AUC,. at the time points studied.
Figure 8 shows the rates obtained for the unmodified F9 in com-
parison with those for PEG-F9. In all tissues except the liver, the KS,
rate was decreased by PEGylation (Figure 8, top). The K.. rates,
decreased after PEGylation for tumour, muscle, colon and lung. In
contrast, in liver, spleen and kidney PEG-F9 had greater values for
K, than F9 (Figure 8, bottom). The magnitude of change for the
rates was different in every tissue and did not follow a simple pattern
(data not shown). For both K. and Kut, there was no correlation
(P>0.1) between the proportional change in rate constant produced
by PEG, AK. and AK.,, (defined as K. (PEG-F9)/KR(F9) and &u,
(PEG-F9)/K.(F) respectively) and the corresponding rate constant
for the unmodified F9. The qualitative and quantitative differences in
the changes to rate constants suggest that the biological mechanisms
by which F9 enters and exits the tissues and the tumour are tissue
specific and also that PEGylation affects these mechanisms to diffe-
rent extents. It is interesting that in the case of the liver both K and
K.ut rates might increase with PEGylation since it implies that some
mechanisms might be facilitated by PEG. An increased K.. rate is
unlikely to be due to increased destruction by the liver (since PEG-
ylation in general protects from proteolysis) and might indicate fac-
ilitated diffusion of the PEG-F9 towards the lymphatic drainage and
therefore improved tissue penetration. An increased K&u for the ki-
dney might represent return to the circulation of those PEG-F9 co-
njugates that can not be filtered.
Further studies should address what biological mechanisms parti-
cipate in the biodistribution of proteins and to what extent they are
protein or tissue specific. The dissection of the impact that PEG has
on those mechanisms should help to a rational design of constructs
to target specific tumours or tissues.
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